key: cord-1006640-cpqwhi7g
authors: Bethineedi, Lakshmi Deepak; Suvvari, Tarun Kumar
title: POST COVID-19 cholangiopathy – A deep dive
date: 2021-08-09
journal: Dig Liver Dis
DOI: 10.1016/j.dld.2021.08.001
sha: db5edff61c44eaa62f4741108bf631e93d610e67
doc_id: 1006640
cord_uid: cpqwhi7g

nan

Enteric symptoms are significant in COVID-19 and are sometimes the only symptoms presented by the patient [1] . The common gastrointestinal symptom reported among COVID-19 patients is lack of appetite, nausea, vomiting, diarrhea and abdominal pain/discomfort [1] . Alteration in respiratory tract microbial flora can damage the gastrointestinal tract through immune activation, also known as the 'gut-lung-axis' [2] . When the infection is directly through the gastrointestinal tract, it can spread to the respiratory tract through blood [2] . In such cases, gastrointestinal symptoms precede the respiratory symptoms causing misconception of mild gastrointestinal infections and lethal outcomes.

Post-COVID-19 cholangiopathy is a special entity of liver injury that has been suggested as a variant of secondary sclerosing cholangitis in critically ill patients. It usually involves damage to the liver and gallbladder. It might be secondary to infection by the SARS-CoV-2 virus or by drug-induced damage that causes deterioration of the parenchymal cells causing loss of function.

Nevertheless, the diagnosis and treatment for this condition are continuously revised as per available information. Cholangiopathy can be caused in multiple other associated diseases like AIDS, cholangiolithiasis, diffuse intrahepatic metastasis, histiocytosis C and many more. The symptoms in cholangiopathy following COVID-19 are not much different from other etiological types [3] .

The molecular explanation could be due to the predominance of the Angiotensin-converting enzyme 2 (ACE2) receptor in the gut and is further confirmed by the presence of SARS-CoV-2 in faecal samples of COVID-19 patient. The presence of viral receptors on the host cell surface in a particular tissue is a major determinant of viral tropism. SARS-CoV-2 cell entry is mediated by the S protein of the virus, which specifically interacts with host ACE2 and transmembrane serine protease 2 (TMPRSS2) [3] . The presence of ACE2 is relatively low in hepatocytes and mainly located in higher levels in cholangiocytes, while the presence of TMPRSS2 is relatively higher in hepatocytes. These findings may be important considering recent reports on endotheliitis of large intrahepatic vessels caused by SARS-CoV-2 and high ACE2 expression in other endothelial, including central and portal veins, which also can become infected by the virus [3, 4] .

Diagnosis mostly depends on the history presented beside the doctor's clinical evaluation, blood tests and imaging studies. Ultrasonography helps clinicians to visualize the ducts but does not helps in clinching the diagnosis firmly. For more clear conclusive reports, magnetic resonance imaging of the bile ducts or endoscopic retrograde cholangiopancreatography is required [4, 5] .

Disruption of intestinal wall mucosa can lead to disseminating the virus from the gastrointestinal tract to blood and liver by the portal tract system. It is then excreted in bile, causing more widespread circulatory spread in the gut besides multiplying in the hepatic (hepatocytes) and gallbladder parenchymal cells [2] . In that scenario, Liver function tests could show elevated liver enzymes, i.e., aspartate transferase, alanine transferase, and total bilirubin [6] . Cai Q et al.

reported that gamma-glutamyl transferase in serum is increased to thrice the normal levels [7] . biopsy, which showed moderate portal to peri-portal fibrosis [9] . The 3 patients had prolonged hospitalization due to acute respiratory failure, and liver enzymes were slightly elevated during the hospital stay. Persistent cholestasis and jaundice were noticed even after cardiopulmonary and renal recovery. No cirrhosis was found, and intrahepatic microangiopathy suggests the direct hepatic injury due to COVID-19. None of the 3 patients have chronic liver disease in the past [9] .

Alkaline phosphatase, Aspartate aminotransferase, Alanine aminotransferase and total bilirubin levels were found normal at the time of admission time, but peaks reaching 10-100 times of initial values were found later reducing to baseline after covid-19 recovery. 

Gastrointestinal sequelae 90 days after discharge for COVID-19

The mechanism and treatment of gastrointestinal symptoms in patients with COVID-19

Pathophysiological mechanisms of liver injury in COVID-19

Ischemic cholangiopathy

Liver injury in COVID-19: management and challenges

COVID-19: Abnormal liver function tests

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Post-COVID-19 Cholangiopathy: A Novel Entity

Post-Covid-19 Cholangiopathy-A New Indication for Liver Transplantation: A Case Report